Author:
Kwan E. M.,Thangasamy I. A.,Teh J.,Alghazo O.,Sathianathen N. J.,Lawrentschuk N.,Azad A. A.
Funder
National Health and Medical Research Council
Victorian Cancer Agency
Astellas Pharma US
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. American Cancer Society (2017) Cancer facts and figures 2017. American Cancer Society, Atlanta
2. Huggins C, Hodges CV (1941) Studies on prostatic cancer I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1(4):293
3. Kunath F, Goebell PJ, Wullich B, Sikic D, Kahlmeyer A (2019) Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. World J Urol. https://doi.org/10.1007/s00345-019-02704-y
4. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–58
5. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–46
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献